Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2018-01-02 Regulatory Filings
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Rozpoczęcie współpracy w zakresie wyłącznej dystrybucji produktów w Egipcie, Katarze i Bahrajnie. - Content (PL)
Regulatory Filings Classification · 95% confidence The document text describes a new exclusive distribution agreement for dermocosmetics in Egypt, Qatar, and Bahrain. It details the terms, minimum sales requirements (100k EUR), and the strategic importance of this expansion. This type of announcement, detailing a significant business development or contract that impacts future revenue, does not fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS). It is a general business update concerning market expansion and sales channels. Given the available categories, this is best classified as a general Regulatory Filing (RNS) as it is a material business event announcement that doesn't match a more specific category like M&A (TAR) or Financing (CAP). The document length (1201 chars) suggests it is the primary announcement, not just a link to a report.
2018-01-02 Polish
Przedłużenie wyłączności na dystrybucję produktów w Chinach, Hong Kongu, Makao oraz na Tajwanie - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Management Board ('Zarząd') of Pharmena S.A. It references a previous report (nr 9/2017) and details the fulfillment of a minimum sales threshold (350k EUR) by a distributor for the year 2017, which secures the distributor's exclusivity for the following year (2018 target: 850k EUR). This type of communication, detailing the status of a significant commercial agreement and its implications for future revenue, is characteristic of a current report or material event disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it concerns a material business development, it fits best under the general category for regulatory announcements that are not otherwise specified. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a material, non-standardized corporate event disclosure in Polish, especially since it doesn't fit the specific definitions like DIRS, DIV, or CAP. The document length (1555 chars) is short, but it contains the core information, not just an announcement *about* a report.
2017-12-19 Polish
Przedłożenie uwag do projektu rozporządzenia Komisji ws. autoryzacji 1-MNA jako nowego składnika żywności - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a current report (raport bieżący) from PHARMENA S.A. regarding its submission of comments on a draft EU regulation concerning 1-MNA as a novel food ingredient. It discusses regulatory processes, scientific data protection, and the potential material impact on the issuer's revenue if authorization is granted. This content relates to legal/regulatory matters concerning the company's product pipeline and compliance, but it is not a formal legal proceeding report (LTR), nor is it a standard financial report (10-K, IR, ER). It is a specific update on regulatory interaction. Given the options, this type of specific, non-standard regulatory update that doesn't fit into the primary financial or governance categories is best classified as a general Regulatory Filing (RNS), as it is an announcement of an action taken in response to a regulatory development.
2017-11-10 Polish
Otrzymanie projektu rozporządzenia Komisji ws. autoryzacji 1-MNA jako nowego składnika żywności - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal communication from the Management Board (Zarząd) of PHARMENA S.A. referencing previous reports and providing an update on regulatory progress concerning a new food ingredient (1-MNA) authorization by EFSA and the receipt of a draft implementing regulation from the European Commission. It discusses the potential impact on future revenues. This type of update, which concerns regulatory steps, legal/administrative processes, and potential business impact, fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if it were a lawsuit, but here it is a regulatory administrative update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change, and it is a direct regulatory update, RNS is the most appropriate general regulatory filing category, especially given the short length and nature of the announcement (Rule 2).
2017-11-08 Polish
Korekta raportu nr 16/2017 pt. „Pozytywna opinia naukowa EFSA o autoryzację 1-MNA jako nowego składnika żywności” - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a correction ('koryguje') to a previous current report (raport nr 16/2017) filed via the ESPI system. It discusses the receipt of a positive scientific opinion from EFSA regarding the authorization of a new food ingredient (1-MNA) and explains why the disclosure of this confidential information was delayed. This type of announcement, detailing specific corporate events, regulatory milestones, or corrections to prior disclosures, is characteristic of ongoing regulatory reporting rather than a comprehensive annual report (10-K), an earnings release (ER), or a general presentation (IP). Since it is a specific, material, non-standard announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), it falls best under the general regulatory announcement category, RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory disclosures not covered elsewhere.
2017-10-26 Polish
Pozytywna opinia naukowa EFSA o autoryzację 1-MNA jako nowego składnika żywności - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal communication from the Management Board (Zarząd) of PHARMENA S.A. regarding the publication of a positive scientific opinion by EFSA concerning the authorization of a new food ingredient (1-MNA). It references previous reports (raport bieżący nr 15/2017) and details the regulatory steps involving EFSA and the European Commission. The text is an update on a regulatory/approval process, not the full financial report (10-K, IR) or a general announcement of a report's release (RPA). Since it concerns a specific regulatory development (product authorization status) that doesn't fit perfectly into the other specific categories like M&A, Capital Change, or Dividend, it falls best under the general 'Regulatory Filings' category (RNS) as a significant, non-standard regulatory update, or potentially LTR if viewed as a regulatory proceeding, but RNS is the broader fit for miscellaneous regulatory news not covered elsewhere. Given the context of product approval updates, RNS is the most appropriate fallback.
2017-10-26 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.